| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Fmoc-alpha-allyl-L-alanine does not have a specific pharmacological target as it is a protected amino acid derivative used as a synthetic intermediate. Its function is to serve as a building block for the synthesis of peptides and peptide-like molecules. The Fmoc protecting group is used to selectively protect the amine functionality during peptide synthesis, allowing for the controlled assembly of peptide chains. The allyl group on the α-carbon provides a handle for further functionalization through reactions such as olefin metathesis, allowing for the introduction of various modifications. The compound is used in medicinal chemistry for the synthesis of peptide-based drugs and chemical probes. The compound's utility lies in its role as a versatile building block for organic synthesis and drug discovery.
|
|---|---|
| ln Vitro |
In vitro, Fmoc-alpha-allyl-L-alanine is used as a synthetic intermediate in peptide synthesis. The compound is used to incorporate allyl-substituted amino acids into peptides and peptide-like molecules using solid-phase peptide synthesis. In SPPS, the compound is coupled to a resin-bound peptide chain using standard coupling reagents such as HATU, HOBt, or DIC. The Fmoc protecting group is removed using piperidine to expose the amine for the next coupling step. The allyl group can be used for post-synthetic modifications through olefin metathesis, allowing for the introduction of various functional groups. The compound's purity and identity are confirmed by HPLC and NMR spectroscopy. The compound is typically stored at -20°C and protected from moisture.
|
| ln Vivo |
In vivo, Fmoc-alpha-allyl-L-alanine is not used as a therapeutic agent but as a synthetic intermediate for the preparation of peptide-based compounds. The compound itself is not biologically active and is used solely as a chemical building block. The compound may be used in the synthesis of peptide drugs or chemical probes that contain allyl-substituted amino acids. The allyl group allows for the introduction of various modifications that can modulate the biological activity of peptides. However, Fmoc-alpha-allyl-L-alanine is a protected precursor that requires deprotection and modification to yield the active compound. The compound is intended for research use only and is not approved for clinical use. Its role is limited to chemical synthesis and drug discovery.
|
| Enzyme Assay |
In vitro synthetic procedures using Fmoc-alpha-allyl-L-alanine typically involve solid-phase peptide synthesis techniques. The compound is dissolved in appropriate solvents such as DMF or NMP for coupling reactions. In SPPS, the compound is activated using coupling reagents such as HATU, HOBt, or DIC and coupled to resin-bound peptides. The Fmoc protecting group is removed using 20% piperidine in DMF. The allyl group can be used for post-synthetic modifications through olefin metathesis using catalysts such as Grubbs' catalyst. The compound's purity and identity are confirmed by HPLC and mass spectrometry. The compound is typically stored at -20°C and protected from moisture. For long-term storage, the compound should be kept in a dry place and protected from light.
|
| Cell Assay |
Cell-based assays using Fmoc-alpha-allyl-L-alanine are not typical as the compound is a synthetic intermediate rather than a bioactive molecule. However, the compound may be used to synthesize peptides that are tested in cell-based assays. The compound itself would not be expected to have significant biological activity due to the presence of the protecting groups. For studies involving allyl-substituted peptides, the protected compound would be used in peptide synthesis, and the final peptide would be deprotected and modified before testing. The compound's solubility in organic solvents makes it suitable for use in peptide synthesis. The compound is not typically used directly in cell culture experiments. Its role is limited to chemical synthesis and drug discovery.
|
| Animal Protocol |
In vivo animal experiments using Fmoc-alpha-allyl-L-alanine are not typical as the compound is a synthetic intermediate rather than a therapeutic agent. The compound may be used in the synthesis of peptide-based drugs that are subsequently tested in animal models. The compound itself is not administered to animals for therapeutic purposes. Its role is limited to chemical synthesis and drug discovery. The compound's pharmacokinetic and toxicity properties have not been characterized as it is not intended for in vivo use. The compound is intended for research use only and is not approved for clinical use. Standard laboratory safety precautions should be followed when handling the compound.
|
| ADME/Pharmacokinetics |
Fmoc-alpha-allyl-L-alanine has a molecular weight of approximately 351.40 g/mol and the formula C21H21NO4. The compound is soluble in organic solvents such as DMF, NMP, and DCM. For long-term storage, the compound is kept at -20°C in a dry place, protected from moisture. The compound is stable under normal storage conditions. The Fmoc protecting group can be removed under basic conditions (piperidine), and the allyl group can be used for further functionalization. The compound is used as a building block in solid-phase peptide synthesis. Its purity and identity are confirmed by HPLC and NMR spectroscopy. The compound is intended for research use only and is not approved for clinical use.
|
| Toxicity/Toxicokinetics |
The toxicity of Fmoc-alpha-allyl-L-alanine has not been extensively characterized as the compound is a synthetic intermediate rather than a therapeutic agent. The compound is intended for research use only and is not for human use. Standard laboratory safety precautions should be followed when handling the compound, including the use of gloves and eye protection. The compound may cause irritation to skin, eyes, and respiratory tract upon contact. Inhalation of dust should be avoided. The compound is not classified as a highly toxic substance but should be handled with appropriate care. Safety data sheets recommend standard handling procedures for research chemicals. The compound's toxicity in vivo has not been studied as it is not intended for in vivo use. The compound should be handled in a well-ventilated area.
|
| Additional Infomation |
Fmoc-alpha-allyl-L-alanine (CAS 288617-71-0) is a protected amino acid derivative used in peptide synthesis. It has the molecular formula C21H21NO4 and a molecular weight of approximately 351.40 g/mol. The compound contains an Fmoc (9-fluorenylmethoxycarbonyl) protecting group on the amino group and an allyl group on the α-carbon. The allyl group introduces a side chain that can be used for further functionalization through olefin metathesis or other reactions. Fmoc-alpha-allyl-L-alanine is used as a building block for the incorporation of allyl-substituted amino acids into peptides and peptide-like molecules. The compound is used in medicinal chemistry for the synthesis of peptide-based drugs and chemical probes. The Fmoc group is widely used in solid-phase peptide synthesis and can be removed under mild basic conditions (piperidine). The allyl group provides a handle for post-synthetic modifications. The compound is soluble in organic solvents such as DMF, NMP, and DCM. It is intended for research use only and is not approved for clinical use. It is typically stored at -20°C and protected from moisture.
|
| Molecular Formula |
C21H21NO4
|
|---|---|
| Molecular Weight |
351.3957
|
| Exact Mass |
351.147
|
| CAS # |
288617-71-0
|
| PubChem CID |
46737294
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.224g/cm3
|
| Boiling Point |
564.259ºC at 760 mmHg
|
| Flash Point |
295.054ºC
|
| Vapour Pressure |
0mmHg at 25°C
|
| Index of Refraction |
1.595
|
| LogP |
4.335
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
26
|
| Complexity |
526
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O(C(N([H])[C@@](C(=O)O[H])(C([H])([H])[H])C([H])([H])C([H])=C([H])[H])=O)C([H])([H])C1([H])C2=C([H])C([H])=C([H])C([H])=C2C2=C([H])C([H])=C([H])C([H])=C12
|
| InChi Key |
FNCSRFHDUZYOCR-NRFANRHFSA-N
|
| InChi Code |
InChI=1S/C21H21NO4/c1-3-12-21(2,19(23)24)22-20(25)26-13-18-16-10-6-4-8-14(16)15-9-5-7-11-17(15)18/h3-11,18H,1,12-13H2,2H3,(H,22,25)(H,23,24)/t21-/m0/s1
|
| Chemical Name |
(2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-2-methylpent-4-enoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8458 mL | 14.2288 mL | 28.4576 mL | |
| 5 mM | 0.5692 mL | 2.8458 mL | 5.6915 mL | |
| 10 mM | 0.2846 mL | 1.4229 mL | 2.8458 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
